Trump secures agreements with nine drugmakers to reduce medication costs

Nine pharmaceutical companies have committed to President Trump's drug pricing policies, including lowering U.S. prices for some drugs and participating in the upcoming TrumpRx platform, as part of a broader effort to align U.S. drug prices with those in other developed countries and promote domestic manufacturing. The deals involve offering drugs at most favored nation prices, investing in domestic production, and donating ingredients to the national stockpile, though some drugs are already available as generics.